Tesamorelin vs CJC-1295 — how do they actually compare?

Both are GHRH analogs but they get treated very differently in the community. Let's break it down.

Tesamorelin:

• FDA-approved (for HIV lipodystrophy)
• Strong data on reducing visceral fat
• More expensive because of pharmaceutical status
• Some vendors carry the research version
• Well-studied safety profile

CJC-1295 (with DAC):

• Longer half-life than tesamorelin
• More commonly available from research vendors
• Usually paired with a GHRP (ipamorelin, GHRP-2)
• Less clinical trial data but extensive community use

Key difference: Tesamorelin has real clinical data behind it. CJC-1295 has broader community experience but less formal research.

The practical question: If you have access to both, which makes more sense for your research goals? Tesamorelin's visceral fat data is compelling, but CJC+Ipa is the more flexible stack.

What are people running and why did you choose one over the other?